Breakthrough schizophrenia drug shows promise in major trial
NCT ID NCT02469155
Summary
This large Phase 3 study tested whether a new medication called ITI-007 could help control symptoms in people experiencing a sudden worsening of schizophrenia. For 6 weeks, 696 adult patients received either ITI-007, an existing antipsychotic medication, or a placebo pill, with neither patients nor doctors knowing which treatment they received. Researchers measured changes in overall schizophrenia symptoms to see if ITI-007 worked better than placebo and compared to current treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Site
Little Rock, Arkansas, United States
-
Clinical Site
Springdale, Arkansas, United States
-
Clinical Site
Culver City, California, United States
-
Clinical Site
Lemon Grove, California, United States
-
Clinical Site
Long Beach, California, United States
-
Clinical Site
San Diego, California, United States
-
Clinical Site
North Miami, Florida, United States
-
Clinical Site
Berlin, New Jersey, United States
-
Clinical Site
Marlton, New Jersey, United States
-
Clinical Site
Austin, Texas, United States
-
Clinical Site
Dallas, Texas, United States
Conditions
Explore the condition pages connected to this study.